Unlock instant, AI-driven research and patent intelligence for your innovation.

Castration resistant prostate cancer

A technology for castration resistance and prostate cancer, which is applied in the direction of antineoplastic drugs, medical preparations with non-active ingredients, containing abnormal peptide bonds, etc., and can solve the problems of immature clinical tests

Pending Publication Date: 2020-05-15
塔尔格免疫治疗有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Even with preclinical evidence supporting the importance of these molecular pathways, clinical testing of most of these drugs is still immature (Bellmunt et al., 2010, supra)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Castration resistant prostate cancer
  • Castration resistant prostate cancer
  • Castration resistant prostate cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0295] Example 1 - Preparation of polyplexes

[0296] Chemicals for LPEI Synthesis and PEGylation

[0297] NHS-PEG-OPSS (o-pyridyl disulfide-polyethylene glycol-N-hydroxysuccinimide ester), also known as PDP-PEG-NHS (PDP: pyridyl dithiopropionate), with a molecular weight of Approximately 2 kDa, purchased from Creative PEGworks (Winston, USA). Poly(2-ethyl-2-oxazoline), average molecular weight (Mn) about 50 kDa, and anhydrous dimethylsulfoxide (DMSO) were purchased from Sigma-Aldrich (Israel). Absolute ethanol was purchased from Romical (Israel). All solvents were used without further purification.

[0298] Synthesis of LPEI (free base form)

[0299] Synthesis of LPEI and PEGylation of LPEI were performed as previously described (WO 2015 / 173824; Joubran et al., 2014, Optimization of liganded polyethyleneimine polyethylene glycol vector fornucleic acid delivery, Bioconjug Chem 2014, 25(9):1644-1654).

[0300] Briefly, 8.0 g (0.16 mmol) of poly(2-ethyl-2-oxazoline) were hy...

Embodiment 3

[0328] Example 3 - In vitro and in vivo tests

[0329] In vitro analysis of the bystander effect induced by PPD / polyIC treatment

[0330] The co-culture system was used to analyze the PPD / polyIC bystander effect in vitro. Treated PSMA-overexpressing cells were co-cultured with PBMCs alone or with PBMCs and cells not expressing PSMA (to represent adjacent cancer cells). Bystander effects were assessed by cell lines stably expressing luciferase (LNCaP-Luc / GFP, PC3-Luc / GFP or MCF7-Luc / GFP). The viability (luciferase activity) of these cells was measured (Luciferase Assay System, Promega).

[0331] Co-culture system of LNCaP-Luc / GFP-PBMC: Inoculate LNCaP-Luc / GFP cells (10,000 cells / well, 96-well plate pre-coated with polylysine, in triplicate), culture for one day and mix with PPD / polyIC Incubation. After 24 hours, freshly isolated PBMCs (1×10 per well 5 cells) were added to the culture, and the survival (luciferase activity) of LNCaP-Luc / GFP cells was detected after 24 hours...

Embodiment 4

[0336] Example 4 - Results of In Vitro Tests

[0337] Specific binding and uptake of DUPA coupled to Dylight680 via a specific peptide linker into PSMA-overexpressing cells

[0338] This example demonstrates that the PSMA ligand DUPA coupled via a peptide linker to another compound, such as a fluorescent dye or a multimeric complex consisting of PEI-PEG / polyIC, selectively targets PSMA-overexpressing cancer cells and will The polyplexes of the invention are delivered to these compound cells.

[0339] DUPA was coupled to the fluorescent dye Dylight680 (Thermo Scientific) via a specially designed peptide linker consisting of a hydrocarbon chain of 8-aminooctanoic acid, while the short peptide part avoided the steric hindrance of the PSMA ligand DUPA. The peptide linker used in this example included the peptide moiety of SEQ ID NO: 1 (Cys-Gly-Trp-Trp-Gly-Phe, see Figure 1A ).

[0340] Binding of DUPA-linker-Dylight680 conjugates to cancer cells was measured by confocal fluore...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a polyplex for use in the treatment of castration resistant prostate cancer (CRPC) comprising a double stranded RNA (dsRNA) and a polymeric conjugate, wherein said polymeric conjugate consists of a linear polyethyleneimine (LPEl), one or more polyethylene glycol (PEG) moieties, one or more linkers and one or more targeting moieties, wherein said LPEl is covalentlybound to one or more PEG moieties and each of said one or more PEG moieties is conjugated via one of the one or more linkers to one of the one or more targeting moieties, wherein each of said one or more targeting moieties is capable of binding to a cancer antigen, and wherein said cancer antigen is prostate surface membrane antigen (PSMA). Further, the invention relates to a pharmaceutical composition for use in the treatment of CRPC.

Description

technical field [0001] The present invention relates to the field of prostate cancer treatment. In particular, the present invention relates to multimeric complexes and pharmaceutical compositions comprising said multimeric complexes for use in the treatment of castration-resistant prostate cancer (CRPC). The multimeric complex comprises double-stranded RNA (dsRNA) and a polymeric conjugate (polymeric conjugate), wherein the polymeric conjugate is composed of linear polyethyleneimine (LPEI), one or more polyethylene Diol (PEG) moieties, one or more linkers, and one or more targeting moieties, wherein the LPEI is covalently bound to the one or more PEG moieties, and the one or more PEG moieties are each conjugated to one of the one or more targeting moieties via one of the one or more linkers, wherein each of the one or more targeting moieties is capable of binding a cancer antigen, and Wherein the cancer antigen is prostate surface membrane antigen (PSMA). Background techn...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K5/02C07K7/06A61K47/60A61K47/54A61P35/00A61K47/56A61K47/68
CPCA61K47/60C07K7/06A61P35/00A61K47/65A61K47/542A61K47/59C07K7/02C12N15/88C12N15/00A61K47/549
Inventor E·波博-维勒A·列维茨基Y·郎古特M·齐格勒A·希尔E·基塔斯
Owner 塔尔格免疫治疗有限公司